Please use this identifier to cite or link to this item: http://hdl.handle.net/1893/31879
Full metadata record
DC FieldValueLanguage
dc.contributor.authorHapca, Simonaen_UK
dc.contributor.authorSiddiqui, Moneeza Ken_UK
dc.contributor.authorKwan, Ryan S Yen_UK
dc.contributor.authorLim, Michelleen_UK
dc.contributor.authorMatthew, Shonaen_UK
dc.contributor.authorDoney, Alex S Fen_UK
dc.contributor.authorPearson, Ewan Ren_UK
dc.contributor.authorPalmer, Colin N Aen_UK
dc.contributor.authorBell, Samiraen_UK
dc.date.accessioned2020-10-28T01:04:10Z-
dc.date.available2020-10-28T01:04:10Z-
dc.date.issued2021-01en_UK
dc.identifier.urihttp://hdl.handle.net/1893/31879-
dc.description.abstractBackground There are few observational studies evaluating the risk of AKI in people with type 2 diabetes, and even fewer simultaneously investigating AKI and CKD in this population. This limits understanding of the interplay between AKI and CKD in people with type 2 diabetes compared with the nondiabetic population. Methods In this retrospective, cohort study of participants with or without type 2 diabetes, we used electronic healthcare records to evaluate rates of AKI and various statistical methods to determine their relationship to CKD status and further renal function decline. Results We followed the cohort of 16,700 participants (9417 with type 2 diabetes and 7283 controls without diabetes) for a median of 8.2 years. Those with diabetes were more likely than controls to develop AKI (48.6% versus 17.2%, respectively) and have preexisting CKD or CKD that developed during follow-up (46.3% versus 17.2%, respectively). In the absence of CKD, the AKI rate among people with diabetes was nearly five times that of controls (121.5 versus 24.6 per 1000 person-years). Among participants with CKD, AKI rate in people with diabetes was more than twice that of controls (384.8 versus 180.0 per 1000 person-years after CKD diagnostic date, and 109.3 versus 47.4 per 1000 person-years before CKD onset in those developing CKD after recruitment). Decline in eGFR slope before AKI episodes was steeper in people with diabetes versus controls. After AKI episodes, decline in eGFR slope became steeper in people without diabetes, but not among those with diabetes and preexisting CKD. Conclusions Patients with diabetes have significantly higher rates of AKI compared with patients without diabetes, and this remains true for individuals with preexisting CKD.en_UK
dc.language.isoenen_UK
dc.publisherAmerican Society of Nephrology (ASN)en_UK
dc.relationHapca S, Siddiqui MK, Kwan RSY, Lim M, Matthew S, Doney ASF, Pearson ER, Palmer CNA & Bell S (2021) The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study. Journal of the American Society of Nephrology, 32 (1), pp. 138-150. https://doi.org/10.1681/asn.2020030323en_UK
dc.rights[JASN_AKI_CKD_supplemenatry_material_22072020.pdf] The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study, Simona Hapca, Moneeza K. Siddiqui, Ryan S.Y. Kwan, Michelle Lim, Shona Matthew, Alex S.F. Doney, Ewan R. Pearson, Colin N.A. Palmer, Samira Bell, on behalf of the BEAt-DKD Consortium*, JASN Oct 2020, ASN.2020030323; DOI: 10.1681/ASN.2020030323en_UK
dc.rights[AKI_CKD_JASN_final27072020.pdf] The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study, Simona Hapca, Moneeza K. Siddiqui, Ryan S.Y. Kwan, Michelle Lim, Shona Matthew, Alex S.F. Doney, Ewan R. Pearson, Colin N.A. Palmer, Samira Bell, on behalf of the BEAt-DKD Consortium*, JASN Jan 2020, vol. 32 no. 1, pp. 138-150; DOI: 10.1681/ASN.2020030323en_UK
dc.rights.urihttps://storre.stir.ac.uk/STORREEndUserLicence.pdfen_UK
dc.subjectchronic kidney diseaseen_UK
dc.subjectdiabetes mellitusen_UK
dc.subjectepidemiology and outcomesen_UK
dc.subjectacute kidney injuryen_UK
dc.titleThe Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Studyen_UK
dc.typeJournal Articleen_UK
dc.identifier.doi10.1681/asn.2020030323en_UK
dc.identifier.pmid32948670en_UK
dc.citation.jtitleJournal of the American Society of Nephrologyen_UK
dc.citation.issn1533-3450en_UK
dc.citation.issn1046-6673en_UK
dc.citation.volume32en_UK
dc.citation.issue1en_UK
dc.citation.spage138en_UK
dc.citation.epage150en_UK
dc.citation.publicationstatusPublisheden_UK
dc.citation.peerreviewedRefereeden_UK
dc.type.statusNA - Not Applicable (or Unknown)en_UK
dc.type.statusAM - Accepted Manuscripten_UK
dc.contributor.funderWellcomeen_UK
dc.contributor.funderWellcomeen_UK
dc.contributor.funderWellcomeen_UK
dc.contributor.funderWellcomeen_UK
dc.contributor.funderHorizon 2020 Framework Programmeen_UK
dc.contributor.funderInnovative Medicines Initiativeen_UK
dc.contributor.funderEuropean Federation of Pharmaceutical Industries and Associationsen_UK
dc.contributor.funderWellcomeen_UK
dc.citation.date18/09/2020en_UK
dc.description.noteson behalf of the BEAt-DKD Consortiumen_UK
dc.contributor.affiliationComputing Scienceen_UK
dc.contributor.affiliationUniversity of Dundeeen_UK
dc.contributor.affiliationUniversity of Dundeeen_UK
dc.contributor.affiliationNinewells Hospital & Medical Schoolen_UK
dc.contributor.affiliationUniversity of Dundeeen_UK
dc.contributor.affiliationUniversity of Dundeeen_UK
dc.contributor.affiliationUniversity of Dundeeen_UK
dc.contributor.affiliationUniversity of Dundeeen_UK
dc.contributor.affiliationUniversity of Dundeeen_UK
dc.identifier.isiWOS:000605628100014en_UK
dc.identifier.scopusid2-s2.0-85097670470en_UK
dc.identifier.wtid1664089en_UK
dc.contributor.orcid0000-0003-3148-9657en_UK
dc.contributor.orcid0000-0002-6210-5620en_UK
dc.contributor.orcid0000-0001-9100-1575en_UK
dc.date.accepted2020-07-27en_UK
dcterms.dateAccepted2020-07-27en_UK
dc.date.filedepositdate2020-10-27en_UK
rioxxterms.apcnot requireden_UK
rioxxterms.typeJournal Article/Reviewen_UK
rioxxterms.versionAMen_UK
local.rioxx.authorHapca, Simona|0000-0003-3148-9657en_UK
local.rioxx.authorSiddiqui, Moneeza K|en_UK
local.rioxx.authorKwan, Ryan S Y|en_UK
local.rioxx.authorLim, Michelle|en_UK
local.rioxx.authorMatthew, Shona|en_UK
local.rioxx.authorDoney, Alex S F|0000-0002-6210-5620en_UK
local.rioxx.authorPearson, Ewan R|en_UK
local.rioxx.authorPalmer, Colin N A|en_UK
local.rioxx.authorBell, Samira|0000-0001-9100-1575en_UK
local.rioxx.project085475/Z/08/Z|Wellcome|en_UK
local.rioxx.project085475/B/08/Z|Wellcome|en_UK
local.rioxx.project084727/Z/08/Z|Wellcome|en_UK
local.rioxx.project072960/Z/03/Z|Wellcome|en_UK
local.rioxx.projectProject ID unknown|Horizon 2020 Framework Programme|en_UK
local.rioxx.project115974|Innovative Medicines Initiative|en_UK
local.rioxx.projectProject ID unknown|European Federation of Pharmaceutical Industries and Associations|en_UK
local.rioxx.project084726/Z/08/Z|Wellcome|en_UK
local.rioxx.freetoreaddate2020-10-27en_UK
local.rioxx.licencehttps://storre.stir.ac.uk/STORREEndUserLicence.pdf|2020-10-27|en_UK
local.rioxx.filenameAKI_CKD_JASN_final27072020.pdfen_UK
local.rioxx.filecount2en_UK
local.rioxx.source1533-3450en_UK
Appears in Collections:Computing Science and Mathematics Journal Articles

Files in This Item:
File Description SizeFormat 
JASN_AKI_CKD_supplemenatry_material_22072020.pdfSupporting Information386.58 kBAdobe PDFView/Open
AKI_CKD_JASN_final27072020.pdfFulltext - Accepted Version663.46 kBAdobe PDFView/Open


This item is protected by original copyright



Items in the Repository are protected by copyright, with all rights reserved, unless otherwise indicated.

The metadata of the records in the Repository are available under the CC0 public domain dedication: No Rights Reserved https://creativecommons.org/publicdomain/zero/1.0/

If you believe that any material held in STORRE infringes copyright, please contact library@stir.ac.uk providing details and we will remove the Work from public display in STORRE and investigate your claim.